PepFellas Laboratories | Research-Grade Peptides
PEPFELLAS Laboratories • Est. 2026
Research Wiki / Peptide Profile
Peptide Profile

CJC-1295

CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH). It was originally developed to increase half-life and bioavailability compared to endogenous GHRH.

1. Chemical Structure and Biochemistry

CJC-1295 is a tetrasubstituted 29-amino acid peptide. It exists predominantly in two forms in the research community:

  • CJC-1295 without DAC (Modified GRF 1-29): The foundational 29-amino acid chain featuring four amino acid substitutions (to prevent rapid degradation by DPP-IV enzymes). It has a half-life of roughly 30 minutes.
  • CJC-1295 with DAC (Drug Affinity Complex): Includes the addition of a bioconjugation linker that binds to serum albumin in the blood, extending the half-life to nearly 8 days.

2. Mechanism of Action

The peptide acts exclusively at the anterior pituitary gland.

  • GH Secretion: It binds to the GHRH receptor, initiating a signaling cascade that results in the pulsatile release of endogenous growth hormone.
  • IGF-1 Upregulation: The systemic increase in growth hormone directly stimulates the liver to produce Insulin-like Growth Factor 1 (IGF-1), the primary mediator of cellular growth and repair.

3. Research and Applications

Due to its ability to increase growth hormone levels without suppressing the body's natural pulsatile rhythm, it is heavily researched in anti-aging and regenerative medicine.

  • Body Composition: Investigated for promoting lipolysis (fat loss) and increasing lean muscle mass.
  • Tissue Repair: Studied alongside synergistic peptides (like Ipamorelin) to accelerate recovery from injuries, enhance sleep quality, and improve bone density.
Tags: CJC-1295 Modified-GRF-1-29 CJC-1295-No-DAC CJC-1295-with-DAC GHRH-analogue growth-hormone-secretagogue IGF-1 muscle-growth lipolysis anti-aging-peptide